Sign up online today & collaborate
or click here to find out more
London, UK – BTG plc, the specialist healthcare company, today announced the first treatment of patients in South Korea with TheraSphere® – a treatment for primary liver cancer and metastatic colorectal cancer that delivers powerful radiation to tumour cells and minimises the exposure to healthy tissue.
Professor Joseph Yun Hwan Kim, Department of Radiology, Korea University Anam Hospital, Seoul, South Korea, said: “Liver cancer has a high mortality rate in Korea and the disease affects more than 15,000 people each year, especially older men in their 60s and 70s. It is fantastic news that this therapy is now available to physicians to help us treat certain patients who currently live with this condition in South Korea and may develop it in the future.”
TheraSphere® is a targeted therapy that consists of millions of glass microspheres containing radioactive yttrium-90. The microspheres are about 20-30 micrometers in diameter – about a third of the width of a human hair. They are delivered directly to liver tumours through the hepatic artery via catheter. The glass microspheres flow directly into the liver tumour through its blood vessels and become permanently lodged there. Because the procedure delivers the treatment directly to the liver tumour, the radiation destroys the tumour cells with minimal impact to the surrounding normal liver tissue. The radioactive microspheres continue to deliver radiation to the tumour over the course of several weeks after treatment. TheraSphere® can also be used as a bridge to surgical removal of diseased tissue or transplantation in these patients.
James Glasgow, General Manager, BTG Asia, said: “As we continue to build on our presence in Asia, BTG is able to offer innovative healthcare solutions to the patient populations that need them most. Korea is now the third Asian market where we have launched TheraSphere® – a new treatment option for certain individuals affected by liver cancer. There has been a high level of physician and patient interest since TheraSphere® was launched in November, and we hope that this newly available medical intervention will help many individuals affected by liver cancer in South Korea.”
In South Korea, TheraSphere® is approved for the treatment of hepatic neoplasia, which includes both hepatocellular carcinoma (HCC), also known as primary liver cancer, and metastatic liver cancer or cancer that has spread to the liver from another point of origin. Distributed in Korea by BL&H, TheraSphere® is also commercially available in Hong Kong and Singapore. Over 20,000 patients worldwide have been treated with TheraSphere®.
South Korean hospitals have also begun enrolling patients in international clinical studies evaluating TheraSphere® in primary and metastatic liver cancer.